Elsevier

Autoimmunity Reviews

Volume 10, Issue 2, December 2010, Pages 84-89
Autoimmunity Reviews

Review
Modern diagnosis of autoimmune blistering skin diseases

https://doi.org/10.1016/j.autrev.2010.08.007Get rights and content

Abstract

The diagnostic gold standard of autoimmune bullous diseases is the detection of autoantibodies in skin or mucous membranes by direct immunofluorescence microscopy of a perilesional biopsy. The molecular characterisation of several target antigens within the last 10 years has, however, fostered the development of sensitive and specific diagnostic tools that allow the serological diagnosis in about 90% of patients. Based on the recombinant immunodominant portions of the target antigens, ELISA systems are commercially available for the detection of circulating antibodies against desmoglein 1, desmoglein 3, envoplakin, BP180, and BP230. Autoantibodies against the soluble ectodomain of BP180 (LAD-1), laminin 332, type VII collagen, and most recently, laminin γ1 can be detected by Western blotting with recombinant or cell-derived forms of these proteins. The definite differentiation between the various immunobullous disorders that comprise about a dozen entities is increasingly important since more diverse treatment options are employed. Exact diagnosis is also pivotal for the prognosis, since some autoimmune bullous diseases may indicate an underlying tumor. Association with a malignancy has been shown in paraneoplastic pemphigus (in 100%) and anti-laminin 332 mucous pemphigoid (in 25%) In pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid, autoantibodies to desmoglein 3, desmoglein 1, and BP180, respectively, have been shown to correlate with the disease activity. The detection of serum autoantibodies during the course of the disease may thus be helpful in guiding treatment decisions in these patients.

Introduction

Autoimmune blistering dermatoses comprise a heterogeneous group of diseases that are characterized by autoantibodies to structural components of the skin and adjacent mucous membranes. In pemphigus, autoantibodies recognize desmosomal proteins that connect neighbouring keratinocytes, in pemphigoid diseases, hemidesmosomal proteins are targeted, and in dermatitis herpetiformis, autoantibodies typically bind to epidermal and tissue transglutaminase.

Pemphigus and pemphigoid diseases have first been differentiated in 1953 by Lever who described intraepidermal split formation and loss of cell adherence between keratinocytes (acantholysis) as histopathological hallmarks of pemphigus whereas he coined the term “pemphigoid” for disorders in which a subepidermal split formation was typically present [1]. About 10 years later, serum and skin-bound autoantibodies were described in pemphigus and pemphigoid [2], [3] and since then, their detection is a prerequisite for the diagnosis of immunobullous disorders. Subsequently, it became clear that, in contrast to most other autoimmune disease, autoantibodies in these disorders are directly pathogenic which has been clearly demonstrated for pemphigus, bullous pemphigoid, anti-laminin 332 pemphigoid, and epidermolysis bullosa acquisita [4], [5], [6].

The incidence of pemphigus greatly varies between different geographical regions and is estimated in Central Europe and the United States between 1 and 2 new patients/1 million/year [7]. The most frequent autoimmune bullous disorder in Central Europe is bullous pemphigoid (BP) with an annual incidence of about 13 new patients/1 million followed by mucous membrane pemphigoid and pemphigoid gestationis (2 new patients/1 million) [8], [9]. Higher incidences have recently been reported in Great Britain based on a data established on the general practitioner level [10]. Interestingly, BP is the only autoimmune disease whose incidence is increasing with age with an incidence of 150–180 new patients/1 million/year in a population older than 80 years [8], [9]. Surprisingly, the incidence of BP has doubled within the last 10 years in a well-defined region of Germany [9], [11]. This may be due to the increasing age of the general population or the advances in the diagnostic tools. These advances are the focus of this review.

Section snippets

Clinical criteria

Some clinical signs are typical for specific immunobullous diseases, e.g. old age, tense blisters, and severe pruritus for BP, whereas flaccid blisters and a positive Nikolsky sign (induction of an erosion by mechanical friction) are characteristic for pemphigus vulgaris. Those clinical features that are part of the diagnostic criteria are detailed in Table 1. Nevertheless, an autoimmune bullous disease cannot be diagnosed by clinical signs alone and requires the detection of tissue-bound and

Direct immunofluorescence microscopy

The diagnostic gold standard is still the detection of autoantibodies in patients' epidermis/mucosal epithelium by direct immunofluorescence (IF) microscopy. In pemphigus, an intercellular binding of IgG and/or C3 is found in the epidermis/epithelium while in pemphigoid diseases, linear staining of IgG and/or C3 is seen at the dermal–epidermal junction. In patients with dermatitis herpetiformis, granular IgA deposits are typically observed at the dermal papillae. Importantly, cryosections of

Indirect immunofluorescence microscopy

Indirect IF microscopy is a well established screening tool for circulating autoantibodies in autoimmune blistering diseases. In pemphigus, guinea pig or monkey esophagus are the most sensitive substrates while in pemphigoid diseases, human skin, in which dermal–epidermal splitting was induced by incubation in a 1 M NaCl solution, has been identified as the optimal substrate [12]. Latter test allows the differentiation between serum autoantibodies that bind to the roof and those that stain the

Target antigen-specific serological analyses by ELISA and Western blotting

In recent years, recombinant and cell-derived forms of the target antigens have been applied in the development of sensitive and specific assays for the detection of circulating autoantibodies (Table 1). So far, 5 different ELISA systems from 2 companies are available for the diagnosis of pemphigus and pemphigoid diseases (Table 2).

Monitoring autoantibody levels during the course of the disease

In pemphigus foliaceus, pemphigus vulgaris, and BP, autoantibodies against desmoglein 1, desmoglein 3, and BP180, respectively, have been demonstrated to be of pathogenic relevance in animal models [4], [5], [6], [71] and serum autoantibody levels in patients, correlate with disease activity [18], [19], [21], [31], [33]. Since highly sensitive and specific commercial ELISA systems are available for these autoantibodies (Table 2) [18], [19], [21], [31], [33] monitoring autoantibody serum levels

Take-home messages

  • Autoimmune bullous diseases are a heterogeneous group of about a dozen well-defined entities.

  • The incidence of immunobullous disorders greatly varies between different geographical regions and in Central Europe, was shown to have doubled within the last decade.

  • The differentiation between the various entities is important for both treatment and prognosis.

  • The diagnostic gold standard is still the detection of autoantibodies in skin or mucous membranes by direct immunofluorescence microscopy of a

References (71)

  • C. Probst et al.

    Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus

    Clin Chim Acta

    (2009)
  • H. Mouquet et al.

    Detection and characterization of anti-envoplakin linker autoantibodies in paraneoplastic pemphigus using specific bead-based assay

    Clin Immunol

    (2008)
  • D. Zillikens et al.

    Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies

    J Invest Dermatol

    (1997)
  • M. Kobayashi et al.

    BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid

    J Dermatol Sci

    (2002)
  • J. Perriard et al.

    IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180

    J Invest Dermatol

    (1999)
  • S. Hofmann et al.

    Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain

    J Invest Dermatol

    (2002)
  • G. Di Zenzo et al.

    Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid

    Clin Immunol

    (2008)
  • G. Di Zenzo et al.

    Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients

    J Invest Dermatol

    (2004)
  • A. Kromminga et al.

    Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180

    J Autoimmun

    (2000)
  • R. Dopp et al.

    IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity

    J Am Acad Dermatol

    (2000)
  • J.A. Fairley et al.

    Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid

    J Invest Dermatol

    (2005)
  • M. Yoshida et al.

    Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid

    J Dermatol Sci

    (2006)
  • A. Kromminga et al.

    Development of an ELISA for the detection of autoantibodies to BP230

    Clin Immunol

    (2004)
  • M. Skaria et al.

    IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230

    J Invest Dermatol

    (2000)
  • I. Chimanovitch et al.

    IgG1 and IgG3 are the major immunoglobulin subclasses targeting epitopes within the NC16A domain of BP180 in pemphigoid gestationis

    J Invest Dermatol

    (1999)
  • V.P. Saw et al.

    Ocular mucous membrane pemphigoid: diagnosis and management strategies

    Ocul Surf

    (2008)
  • C. Bedane et al.

    Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida

    J Invest Dermatol

    (1997)
  • Z. Lazarova et al.

    Comparative analysis of methods for detection of anti-laminin 5 autoantibodies in patients with anti-epiligrin cicatricial pemphigoid

    J Am Acad Dermatol

    (2004)
  • C.A. Egan et al.

    Anti-epiligrin cicatricial pemphigoid and relative risk for cancer

    Lancet

    (2001)
  • K.A. Rashid et al.

    Antigen specificity in subsets of mucous membrane pemphigoid

    J Invest Dermatol

    (2006)
  • D. Zillikens et al.

    Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP1801

    J Invest Dermatol

    (1999)
  • D. Zillikens et al.

    Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180

    J Invest Dermatol

    (1999)
  • D. Zillikens et al.

    A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone

    J Invest Dermatol

    (1996)
  • M. Chen et al.

    Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita

    J Invest Dermatol

    (1997)
  • C. Rose et al.

    Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet

    J Am Acad Dermatol

    (2009)
  • Cited by (162)

    View all citing articles on Scopus
    View full text